Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
HOT NEWS
Microsampling in Drug Development
Download this scientific journal to learn more. Learn more about the applications, benefits, and key…
تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire Provides Press Release Distribution in Arabic
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…